PMID- 32459519
OWN - NLM
STAT- MEDLINE
DCOM- 20210406
LR  - 20210406
IS  - 1744-8328 (Electronic)
IS  - 1473-7140 (Linking)
VI  - 20
IP  - 6
DP  - 2020 Jun
TI  - Measurable residual disease of acute lymphoblastic leukemia in allograft 
      settings: how to evaluate and intervene.
PG  - 453-464
LID - 10.1080/14737140.2020.1766973 [doi]
AB  - INTRODUCTION: Allogeneic hematopoietic stem cell transplantation (allo-HSCT) 
      remains a curable strategy for acute lymphoblastic leukemia (ALL), especially for 
      adult cases. However, leukemia relapse after allograft restricts the improvement 
      of transplant outcomes. Measurable residual disease (MRD) has been the strongest 
      predictor for relapse after allo-HSCT, allowing MRD-directed preemptive therapy. 
      AREAS COVERED: This manuscript summarizes the detection of MRD in patients with 
      ALL who undergo allo-HSCT, focusing the effects of positive pre-HSCT MRD and 
      post-HSCT MRD on outcomes as well as MRD-directed interventions. EXPERT OPINION: 
      Except for MFC and RQ-PCR, other strategies, such as next-generation sequencing 
      and RNAseq, have been developed for MRD determination. Negative effects of 
      positive MRD peri-transplantation on outcomes of ALL patients were observed both 
      in human leukocyte antigen (HLA)-matched sibling donor transplantation and in 
      alternative donor transplantation. Advances have been made in determining the 
      need for transplant according to MRD evaluation after induction or consolidation 
      therapy. A number of approaches, including CAR-T-cell therapy, antibodies 
      (blinatumomab, etc), targeted therapy (imatinib, etc), transplant donor 
      selection, as well as donor lymphocyte infusion and interferon-alpha, have been 
      successfully used or are promising for peri-transplantation MRD interventions. 
      This progress could lead to the significant improvement of transplant outcomes 
      for ALL patients.
FAU - Sun, Yu-Qian
AU  - Sun YQ
AD  - National Clinical Research Center for Hematologic Disease, Peking University 
      People's Hospital & Peking University Institute of Hematology, Beijing Key 
      Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, P.R.C.
FAU - Li, Si-Qi
AU  - Li SQ
AD  - National Clinical Research Center for Hematologic Disease, Peking University 
      People's Hospital & Peking University Institute of Hematology, Beijing Key 
      Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, P.R.C.
FAU - Zhao, Xiao-Su
AU  - Zhao XS
AD  - National Clinical Research Center for Hematologic Disease, Peking University 
      People's Hospital & Peking University Institute of Hematology, Beijing Key 
      Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, P.R.C.
FAU - Chang, Ying-Jun
AU  - Chang YJ
AUID- ORCID: 0000-0002-6124-6050
AD  - National Clinical Research Center for Hematologic Disease, Peking University 
      People's Hospital & Peking University Institute of Hematology, Beijing Key 
      Laboratory of Hematopoietic Stem Cell Transplantation , Beijing, P.R.C.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20200527
PL  - England
TA  - Expert Rev Anticancer Ther
JT  - Expert review of anticancer therapy
JID - 101123358
SB  - IM
MH  - Adult
MH  - Allografts
MH  - Donor Selection
MH  - Hematopoietic Stem Cell Transplantation/*methods
MH  - Humans
MH  - *Neoplasm, Residual
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology/*therapy
MH  - Recurrence
MH  - Transplantation, Homologous
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Measurable/minimal residual disease
OT  - acute lymphoblastic leukemia
OT  - allogeneic stem cell transplantation
OT  - flow cytometry
OT  - haploidentical transplantation
OT  - intervention
OT  - next-generation sequencing
OT  - real-time quantitative polymerase chain reaction
EDAT- 2020/05/28 06:00
MHDA- 2021/04/07 06:00
CRDT- 2020/05/28 06:00
PHST- 2020/05/28 06:00 [pubmed]
PHST- 2021/04/07 06:00 [medline]
PHST- 2020/05/28 06:00 [entrez]
AID - 10.1080/14737140.2020.1766973 [doi]
PST - ppublish
SO  - Expert Rev Anticancer Ther. 2020 Jun;20(6):453-464. doi: 
      10.1080/14737140.2020.1766973. Epub 2020 May 27.